{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-005633","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.022275+00:00","generated_at":"2026-06-16T03:39:39.190931+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ENDRA Life Sciences closes $4.5M public stock & warrant offering, over-allotment fully exercised","bullets":["Offering of 4,312,500 shares + warrants for 2,156,250 shares at $2.41 per set (2 shares + 1 warrant).","Net proceeds of $4.5 million; warrants exercisable at $1.40 per share for 5 years.","Proceeds to fund working capital, product development, regulatory submissions, and commercialization.","Newbridge Securities acted as sole underwriter; warrants will not be listed on any exchange."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-005633","json":"https://secwatch.observer/filing/0001654954-23-005633.json","markdown":"https://secwatch.observer/filing/0001654954-23-005633.md","text":"https://secwatch.observer/filing/0001654954-23-005633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/0001654954-23-005633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:39:39.190931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19054a0f05b005ff99d6c064e94bc5250657714c","claim":"ENDRA Life Sciences Inc. entered into Underwriting Agreement with Newbridge Securities Corporation valued at approximately $4.5 million (effective 2023-04-27).","evidence_excerpt":"On April 27, 2023, ENDRA Life Sciences Inc. (the “Company,” “we,” “us” and “our”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 3,750,000 shares of our common stock and warrants to purchase up to 1,875,000 shares of our common stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/0001654954-23-005633-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Newbridge Securities Corporation"},{"label":"Value","value":"approximately $4.5 million"},{"label":"Effective","value":"2023-04-27"}],"fact_type":"material_agreement"},{"claim_id":"d202bb0133c03104cd81ede23012fc98cd51edbb","claim":"ENDRA Life Sciences Inc. entered into Warrant Agreement with VStock Transfer, LLC (effective 2023-05-02).","evidence_excerpt":"On May 2, 2023, the Company entered into a Warrant Agent Agreement setting forth the terms and conditions of the warrants (the “Warrant Agreement”) with its transfer agent, VStock Transfer, LLC, which will act as warrant agent for the warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495423005633/0001654954-23-005633-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"VStock Transfer, LLC"},{"label":"Effective","value":"2023-05-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}